cropped-gtc_logo_grey_circle_2022

ASH 23 Posters

GTC - ASH 2023 posters

GTC presented abstracts at ASH 2023

GTC’s posters from 2023 Convention of American Society of Hematology are now available to be downloaded. Please reach out with any questions.

USING NEXT GENERATION SEQUENCING OF FLOW CYTOMETRY CD MARKERS AND MACHINE LEARNING AS A REPLACEMENT TO FLOW CYTOMETRY ANALYSIS FOR THE DIAGNOSIS OF HEMATOLOGIC NEOPLASMS

USING NEXT GENERATION SEQUENCING OF FLOW CYTOMETRY CD MARKERS AND MACHINE LEARNING AS A REPLACEMENT TO FLOW CYTOMETRY ANALYSIS FOR THE DIAGNOSIS OF HEMATOLOGIC NEOPLASMS

LYMPHOMA DIAGNOSIS AND CLASSIFICATION USING NEXT GENERATION SEQUENCING OF 30 CD MARKERS AND MACHINE LEARNING AS AN ALTERNATIVE TO IMMUNOHISTOCHEMISTRY


LYMPHOMA DIAGNOSIS AND CLASSIFICATION USING NEXT GENERATION SEQUENCING OF 30 CD MARKERS AND MACHINE LEARNING AS AN ALTERNATIVE TO IMMUNOHISTOCHEMISTRY

Read more Articles and News from GTC

Combining cell-free RNA with cell-free DNA in liquid biopsy forhematologic and solid tumors
Publications

Combining cell-free RNA with cell-free DNA in liquid biopsy forhematologic and solid tumors

Introducing a novel liquid biopsy approach combining cfRNA and cfDNA sequencing. Our findings demonstrate superior mutation detection with cfRNA, while cfDNA excels in identifying chromosomal aberrations. Elevated cfRNA biomarkers correlate with tumor types, aiding diagnosis. Machine learning predicts cancer types accurately. Host immune response analysis through cfRNA ratios reveals distinct patterns in cancer patients. This integrated approach holds promise for predicting genomic abnormalities and cancer diagnosis

Read More »
San Antonio Breast Cancer Review 2023
Events

San Antonio Breast Cancer Review 2023

John Theurer Cancer presents the 2023 San Antonio Breast Cancer Review: This program, based on data presented at the San Antonio Breast Cancer Symposium 2023, is designed to provide a review of state of the art information on experimental biology, etiology, prevention, diagnosis & therapy of breast cancer/premalignant breast disease to an audience of academic and private physicians and researchers involved in medical, surgical, GYN and radiation therapy, as well as other appropriate health care professionals

Read More »

YOU MAY ALSO ENJOY THESE ARTICLES:

Subscribe to our Newsletter

Get all the critical news and events sent straight to your inbox

Share this post with your friends